Recursion Pharmaceuticals, Inc. RXRX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s financing cash flow?
- Recursion Pharmaceuticals, Inc. (RXRX) reported financing cash flow of -$3.47M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s financing cash flow changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s financing cash flow decreased by 108.6% year-over-year, from $40.53M to -$3.47M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s financing cash flow has grown at a 2.7% compound annual growth rate (CAGR), from $469.64M to $521.53M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.